A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
Completed · Phase 1, Phase 2 · NCT05277571
Conditions: Atopic Dermatitis
At a glance
- Research payments reported, 2025
- $1.9M
- U.S. investigators named
- 18
- Sites paid
- 20
- Planned or actual enrollment
- 109
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- UCB1381 (biological), Placebo (drug)
- Dates
- Started 2022-03-07; completion 2025-09-19
- Results posted
- Not yet
The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB1381 (intravenous and subcutaneous) in healthy study participants and after repeat intravenous dosing in study participants with atopic dermatitis. Efficacy will be assessed following repeat intravenous dosing versus placebo in study participants with atopic dermatitis.
From ClinicalTrials.gov, last updated 2026-07-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $1.9M in research payments for this study in 2025 (445 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Michael E. Borok, MD Specialist · Northridge, CA
- Pedram Ghasri, M.D. Dermatology · Tarzana, CA
- Michael T. Lin, MD Dermatology · Sherman Oaks, CA
- Joel M. Neutel, MD Legal Medicine (non-physician) · Tustin, CA
- David M. Stoll, M.D. Specialist · Beverly Hills, CA
- Leonard J. Dunn, MD Pulmonology · Dunedin, FL
- Lawrence Galitz, M.D. General Practice · Miami Gardens, FL
- Linda Martinez, M.D. Family Medicine · Doral, FL
- Amber N. Pepper, MD Allergy & Immunology · Tampa, FL
- Dareen D. Siri, M.D. Allergy & Immunology · Normal, IL
- John K. Randall, RPH, MD Mohs Surgery · West Lafayette, IN
- Paul L. Bigliardi, PROF Dermatology · Minneapolis, MN
- Brittney J. Schultz Dermatology · Minneapolis, MN
- Kevin R. Stein, M.D. Dermatology · Winston Salem, NC
- Emma Guttman, MD Dermatology · New York, NY
- Neil S. Sadick, M.D. Dermatology · New York, NY
- Yaohan Lam, M.D. Dermatology · Oklahoma City, OK
- Lawrence C. Parish, MD Dermatology · Philadelphia, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Oracle Clinical Research $496,805
- Paddington Testing Co. Inc $312,176
- Central Sooner Research $226,826
- Icahn Institute/genetics $209,730
- Global Clinical Professionals LLC $203,703
- Icahn School of Medicine at Mount Sinai $157,542
- Memorial Research Medical Clinic $84,956
- Clinical Research of West Florida Inc $50,568
- Sneeze, Wheeze and Itch Associates, Llc $28,000
- Regents of Univ of Minnesota $22,053
- Discover Dermatology LLC $15,325
- Amicis Research Center $13,800
- Zenith Research Inc $11,636
- UC Irvine Medical Center- Als & Neuromuscular Center $8,150
- Cura Clinical Research $7,050
- Sadick Research Group LLC $4,000
- Options Research Group $1,375
- Amicis Research Center (valencia) $1,148
- Clinical Research of West Florida Incorporated $319
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.